HCB303
Solid Tumors, Hematologic Malignancies
PreclinicalActive
Key Facts
About HanchorBio
A clinical-stage biotech using its FBDB™ platform to develop multi-specific fusion proteins targeting immune checkpoints for oncology and autoimmune diseases.
View full company profileTherapeutic Areas
Other Solid Tumors, Hematologic Malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| HCB301 | HanchorBio | Phase 1 |